{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jo Y"],"funding":["Centers for Disease Control and Prevention","National Center for HIV/AIDS, Viral Hepatitis, STD","Prevention Epidemiologic and Economic Modeling","NCHHSTP CDC HHS","Intramural CDC HHS","CDC HHS"],"pagination":["e3476-e3482"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8077726"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["73(9)"],"pubmed_abstract":["<h4>Background</h4>Targeted testing and treatment (TTT) for latent tuberculosis (TB) infection (LTBI) is a recommended strategy to accelerate TB reductions and further TB elimination in the United States. Evidence on cost-effectiveness of TTT for key populations can help advance this goal.<h4>Methods</h4>We used a model of TB transmission to estimate the numbers of individuals who could be tested by interferon-γ release assay and treated for LTBI with 3 months of self-administered rifapentine and isoniazid (3HP) under various TTT scenarios. Specifically, we considered rapidly scaling up TTT among people who are non-US-born, diabetic, living with human immunodeficiency virus (HIV), homeless or incarcerated in California, Florida, New York, and Texas-states where more than half of US TB case"],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pubmed_title":["Model-based Cost-effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York, and Texas."],"pmcid":["PMC8077726"],"funding_grant_id":["CC999999","5U38PS004646","U38 PS004646"],"pubmed_authors":["Hill A","Marks S","Dowdy D","Asay G","Jo Y","Shrestha S","Gomes I"],"additional_accession":[]},"is_claimable":false,"name":"Model-based Cost-effectiveness of State-level Latent Tuberculosis Interventions in California, Florida, New York, and Texas.","description":"<h4>Background</h4>Targeted testing and treatment (TTT) for latent tuberculosis (TB) infection (LTBI) is a recommended strategy to accelerate TB reductions and further TB elimination in the United States. Evidence on cost-effectiveness of TTT for key populations can help advance this goal.<h4>Methods</h4>We used a model of TB transmission to estimate the numbers of individuals who could be tested by interferon-γ release assay and treated for LTBI with 3 months of self-administered rifapentine and isoniazid (3HP) under various TTT scenarios. Specifically, we considered rapidly scaling up TTT among people who are non-US-born, diabetic, living with human immunodeficiency virus (HIV), homeless or incarcerated in California, Florida, New York, and Texas-states where more than half of US TB case","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2025-04-29T11:31:00.641Z","creation":"2025-04-06T19:54:14.566Z"},"accession":"S-EPMC8077726","cross_references":{"pubmed":["32584968"],"doi":["10.1093/cid/ciaa857"]}}